Search research articles
Contact Us
Filters
Showing results (91-100 of 132) with videos related to
Page
of 14
Sort By:
Antiviral Therapy
|
August 18, 2012
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
Chen-Hua Liu, Cheng-Chao Liang, Chun-Jen Liu, et al.
Antiviral Therapy
|
February 4, 2012
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
Chen-Hua Liu, Cheng-Chao Liang, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 24, 2025
Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases
Tai-Chung Tseng, Yao-Chun Hsu, Tung-Hung Su, et al.
Hepatology (Baltimore, Md.)
|
March 25, 2006
Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study
Chun-Jen Liu, Ming-Yang Lai, You-Chen Chao, et al.
Plos One
|
November 27, 2014
Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma
Hsiang-Yun Cheng, Pei-Jen Kang, Ya-Hui Chuang, et al.
Hepatology (Baltimore, Md.)
|
November 2, 2018
Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase
Ya-Hui Wang, Ya-Hui Chuang, Chih-Feng Wu, et al.
Alimentary Pharmacology & Therapeutics
|
October 27, 2018
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 7, 2008
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial
Chen-Hua Liu, Chun-Jen Liu, Chih-Lin Lin, et al.
Antiviral Therapy
|
August 6, 2011
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
Tai-Chung Tseng, Ming-Lung Yu, Chun-Jen Liu, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 132) with videos related to
Sort By:
Page
of 14
Antiviral Therapy
|
August 18, 2012
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
Chen-Hua Liu, Cheng-Chao Liang, Chun-Jen Liu, et al.
Antiviral Therapy
|
February 4, 2012
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
Chen-Hua Liu, Cheng-Chao Liang, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 24, 2025
Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases
Tai-Chung Tseng, Yao-Chun Hsu, Tung-Hung Su, et al.
Hepatology (Baltimore, Md.)
|
March 25, 2006
Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study
Chun-Jen Liu, Ming-Yang Lai, You-Chen Chao, et al.
Plos One
|
November 27, 2014
Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma
Hsiang-Yun Cheng, Pei-Jen Kang, Ya-Hui Chuang, et al.
Hepatology (Baltimore, Md.)
|
November 2, 2018
Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase
Ya-Hui Wang, Ya-Hui Chuang, Chih-Feng Wu, et al.
Alimentary Pharmacology & Therapeutics
|
October 27, 2018
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 7, 2008
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial
Chen-Hua Liu, Chun-Jen Liu, Chih-Lin Lin, et al.
Antiviral Therapy
|
August 6, 2011
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
Tai-Chung Tseng, Ming-Lung Yu, Chun-Jen Liu, et al.
Page
of 14